Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is accumulating evidence that the AGEs-RAGE interaction plays an important role in accelerated atherosclerosis in diabetes.
|
31378770 |
2019 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Systemic RAGE ligands are upregulated in tuberculosis individuals with diabetes co-morbidity and modulated by anti-tuberculosis treatment and metformin therapy.
|
31818258 |
2019 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Through the detection of protein expression, EGCG was observed to possess the ability to downregulate the accumulation of AGE-RAGE in pancreatic tissues as well as in the transcription factor nuclear factor-κB (NF-κB), which represents a potentially significant method by which EGCG influences diabetes.
|
30582209 |
2018 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High mobility group protein B1 (HMGB1) is a RAGE (also known as AGER) agonist whose levels are increased in diabetes and that contributes to pain by modulating peripheral inflammatory responses.
|
29930087 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Irbesartan attenuates advanced glycation end products-mediated damage in diabetes-associated osteoporosis through the AGEs/RAGE pathway.
|
29702126 |
2018 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since reduced HMGB1 binds to RAGE but not to TLR4, redox modification of HMGB1 as a mechanism regulating the cross-talk between apoptosis and autophagy in diabetes is discussed.
|
28695466 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sugar makes neutrophils RAGE: linking diabetes-associated hyperglycemia to thrombocytosis and platelet reactivity.
|
28504654 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two-week infusion of RAGE-aptamer just after the induction of diabetes also inhibited the AGE-RAGE-oxidative stress system and MCP-1 levels in the kidneys of 8-week-old diabetic rats and simultaneously ameliorated podocyte injury and albuminuria.
|
28385802 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Streptozotocin was used to induce diabetes in both wild type and RAGE knockout mice.
|
27869797 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We serially evaluated experimental DPN in male and female wild-type mice and male RAGE null (RN) mice, each with nondiabetic controls, during 16 wk of diabetes, the final 8 wk including groups given intranasal insulin.
|
28223295 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advanced glycation end products generated by chronic hyperglycemia and their receptor RAGE provide critical links between diabetes and AD.
|
27156888 |
2017 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advanced glycation end products impair the functions of saphenous vein but not thoracic artery smooth muscle cells through RAGE/MAPK signalling pathway in diabetes.
|
27297874 |
2016 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Cox regression model validated four significant variables associated with microalbuminuria: RAGE 374AA (HR 4.19 [1.84-9.58] (p = 0.001)), CYBA TT+TC (HR 2.1 [1.16-3.80], p = 0.015), male sex (HR 1.92 [1.07-3.43], p = 0.028) and diabetes diagnosis at the pediatric stage (HR 1.85 [1.03-3.32], p = 0.039).
|
26607824 |
2016 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The activation of AGEs/RAGE/ROS pathway may be involved in the pathogenesis of vascular complications in diabetes.
|
27914528 |
2016 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The association between the RAGE G82S polymorphism, sRAGE and chronic periodontitis in Taiwanese individuals with and without diabetes.
|
25988707 |
2015 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diabetes leads to accelerated generation of advanced glycation end products (AGEs) and activation of their receptor, RAGE, as well as activation of NAD(P)H oxidase (Nox), an enzyme dedicated to the production of reactive oxygen species, which ultimately leads to a pro-inflammatory environment characterised by oxidative stress.
|
26323666 |
2015 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present study aimed to examine the relationship between RAGE expression in peripheral blood monocytes and circulating sRAGE and esRAGE (endogenous sRAGE, a splice variant of sRAGE) in Type 2 diabetes.
|
20726839 |
2011 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RAGE engagement produces activation of multiple intracellular signaling mechanisms involved in several inflammation-associated clinical entities, such as diabetes, cancer, renal and heart failures, as well as neurodegenerative diseases.
|
20028726 |
2010 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pharmacological blockade of RAGE or genetic deletion of RAGE imparts significant protection in murine models of diabetes, inflammatory conditions, Alzheimer's disease, and tumors.
|
19477910 |
2009 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strategies to reduce the ligation of AGEs to their receptors such as agents which reduce AGE accumulation, soluble RAGE which acts as a competitive antagonist to the binding of AGEs to RAGE and genetic deletions of RAGE appear to attenuate diabetes associated atherosclerosis.
|
18473849 |
2008 |
Diabetes
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrated that PEDF could inhibit diabetes- or AGE-induced RAGE gene expression by blocking the superoxide-mediated NF-kappaB activation.
|
17284935 |
2007 |
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that therapeutic RAGE blockade will intercept maladaptive diabetes-associated memory in the vessel wall and provide cardiovascular protection in diabetes.
|
16305050 |
2004 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The minor allele of a polymorphism located in the promoter region of the RAGE gene (C-1152A) conferred a weak protective effect (P < 0.05) and was associated with a longer duration of nephropathy-free diabetes (P = 0.08).
|
11334430 |
2001 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM.
|
11457670 |
2001 |
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Characterization of allelic and nucleotide variation between the RAGE gene on chromosome 6 and a homologous pseudogene sequence to its 5' regulatory region on chromosome 3: implications for polymorphic studies in diabetes.
|
11723045 |
2001 |